New Thread

Ctrl

I

SPDR S&P Pharmaceuticals ETF Stock Price: Quote, Forecast, Splits & News (XPH)

Perplexity Finance

/

Company Profile

SPDR S&P Pharmaceuticals ETF Price & Performance (XPH)

Stock Performance

Updated Apr 30, 6:10 PM UTC

SPDR S&P Pharmaceuticals ETF

$41.21USD

+$0.12 (+0.29%)

Open

$40.81

Market Cap

$226.67M

Volume 24h

$285.75K

High

$41.27

P/E Ratio

15.6

Year High

$48.76

Low

$40.80

Dividend Yield

1.60%

Year Low

$35.22

Open

$40.81

Market Cap

$226.67M

Year High

$48.76

High

$41.27

P/E Ratio

15.6

Year Low

$35.22

Low

$40.80

Dividend Yield

1.60%

Volume 24h

$285.75K

What's Happening

Peers

iShares U.S. Pharmaceuticals ETF
$68.24
IHE:AMEX
0.52%
Invesco Dynamic Pharmaceuticals ETF
$81.78
PJP:AMEX
0.51%
SPDR S&P Health Care Services ETF
$95.69
XHS:AMEX
0.58%
SPDR S&P Health Care Equipment ETF
$78.68
XHE:AMEX
1.65%
SPDR S&P Oil & Gas Equipment & Services ETF
$57.09
XES:AMEX
3.81%

Related

Financial information provided by Financial Modeling Prep. Options data provided by Unusual Whales. Live transcripts provided by Quartr. Reported revenue and EPS data from Earnings powered by FinChat.io. All data is provided for informational purposes only, and is not intended for trading purposes or financial, investment, tax, legal, accounting or other advice. · See all tickers.

Overview
Latest News
Earnings
Related

Go Deeper

How might recent underperformance of XPH compared to PPH impact investor sentiment in the coming months?
Will ongoing volatility in the broader U.S. stock market influence short-term price swings in XPH?
Could changes in the pharmaceutical sector, such as new drug approvals or regulatory shifts, significantly affect XPH’s top holdings?
How might the risk of XPH becoming 'non-diversified' due to index changes alter its volatility and returns?
Are lower expense ratios and equal-weighted exposure enough to attract new investors despite XPH’s recent negative returns?

Latest News

Healthcare Sector Faces Divergence as Insurers Lag, Pharma Stocks Rally
Apr 21, 2025
Recent trading has highlighted a growing split in healthcare ETFs, with insurers like UnitedHealth dragging down broader funds, while pharmaceutical-focused ETFs such as IHE and XPH have surged on the back of innovation and strong earnings from companies like Eli Lilly. This underscores the need for selective investing within the sector.123
Investor Activity Shifts in SPDR S&P Pharmaceuticals ETF as Institutions Boost Holdings
Apr 12, 2025
Institutional investors, including Wells Fargo and JPMorgan Chase, have significantly increased their positions in the SPDR S&P Pharmaceuticals ETF (XPH) in the last quarter. The ETF has rebounded recently, reflecting renewed confidence in pharmaceutical stocks despite earlier sector-wide headwinds. XPH’s low P/E ratio and broad exposure attract value-seeking investors.45
SPDR Portfolio S&P 500 Growth ETF Sees Mixed Flows Amid Market Volatility
Apr 24, 2025
The SPDR Portfolio S&P 500 Growth ETF (SPYG) is experiencing both increased buying and selling by institutional investors, as market participants adjust portfolios in response to ongoing volatility. Despite a slight uptick in share price, the ETF’s performance remains closely tied to broader economic uncertainties and shifting growth stock sentiment.6